Entrada Therapeutics, Inc. (TRDA) Balance Sheet
TRDA balance sheet, 2025
December 31, 2025 · U.S. dollars$377.4M assets = $71.2M liabilities + $306.1M equity
Both columns are drawn to the same scale: what TRDA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
TRDA financial health
Descriptive bands, not a rating. Fiscal 2025.
TRDA balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $18.2M2019 | $377.4M2025 | +65.7%/yr | |
| Total liabilities | $33.8M2019 | $71.2M2025 | +13.3%/yr | |
| Shareholders’ equity | −$15.5M2019 | $306.1M2025 | — | |
| Cash & short-term investments | $16.8M2019 | $295.7M2025 | +61.2%/yr | |
| Total debt | $25.9M2022 | $50.9M2025 | +25.2%/yr | |
| Net cash (debt) | $162.8M2022 | $244.8M2025 | +$82.0M | |
| Working capital | $15.5M2019 | $281.8M2025 | +$266.3M | |
| Book value per share | −$1.332020 | $7.402025 | — | |
| Debt / equity | 0.122022 | 0.172025 | +0.04 | |
| Shares outstanding | 31.2M2020 | 41.4M2025 | +5.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TRDA assets
TRDA liabilities and equity
TRDA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
TRDA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $295.7M | $420.0M | $352.0M | $188.7M | $291.1M | $39.0M | $16.8M |
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M | $39.0M | $16.8M |
| Short-term investments | $205.3M | $318.8M | $284.4M | $143.6M | $0 | — | — |
| Receivables | $2.6M | $3.7M | $5.9M | $0 | $872,000 | $0 | $0 |
| Inventory | $0 | $0 | $1 | $0 | $0 | $0 | $0 |
| Other current assets | $8.0M | $16.4M | $11.9M | $21.2M | $6.8M | $904,000 | $593,000 |
| Total current assets | $306.3M | $440.0M | $369.8M | $209.9M | $298.7M | $39.9M | $17.4M |
| Property, plant & equipment (net) | $67.8M | $82.0M | $92.7M | $33.0M | $6.3M | $3.0M | $801,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $3.4M | $4.2M | $6.7M | $9.2M | $872,000 | $541,000 | $0 |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M | $43.5M | $18.2M |
| Liabilities | |||||||
| Accounts payable | $2.3M | $4.3M | $3.3M | $6.0M | $706,000 | $1.6M | $710,000 |
| Short-term debt | $4.1M | $7.6M | $7.9M | $8.4M | — | — | — |
| Deferred revenue | $342,000 | $13.7M | $132.3M | — | — | — | — |
| Total current liabilities | $24.5M | $39.5M | $158.8M | $22.0M | $6.7M | $3.4M | $1.9M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $50.9M | $59.2M | $68.2M | $25.9M | $0 | — | — |
| Other long-term liabilities | $46.8M | $58.2M | $68.0M | $17.5M | $396,000 | $81.7M | $31.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M | $85.0M | $33.8M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $4,000 | $4,000 | $3,000 | $3,000 | $3,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$273.1M | −$129.3M | −$195.0M | −$188.3M | −$93.7M | −$42.5M | −$16.0M |
| Accumulated other comprehensive income | $652,000 | −$43,000 | $195,000 | −$2.1M | $0 | −$81.7M | −$31.8M |
| Total shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M | −$41.5M | −$15.5M |
| Key figures | |||||||
| Total debt | $50.9M | $59.2M | $68.2M | $25.9M | — | — | — |
| Net cash (debt) | $244.8M | $360.8M | $283.7M | $162.8M | — | — | — |
| Working capital | $281.8M | $400.6M | $211.0M | $187.9M | $292.0M | $36.6M | $15.5M |
| Tangible book value | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M | −$41.5M | −$15.5M |
| Book value per share | $7.40 | $10.99 | $7.33 | $6.79 | $9.57 | −$1.33 | — |
| Shares outstanding | 41.4M | 39.0M | 33.1M | 31.3M | 31.2M | 31.2M | — |
| Current ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Quick ratio | 12.20 | 10.73 | 2.25 | 8.59 | 43.45 | 11.62 | 8.77 |
| Debt / equity | 0.17 | 0.14 | 0.28 | 0.12 | — | — | — |
| Equity / assets | 81.1% | 81.4% | 51.7% | 84.3% | 97.7% | −95.3% | −85.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $223.0M | $254.9M | $295.7M | $326.8M | $354.0M | $382.5M | $420.0M | $449.3M | $469.7M | $327.4M | $352.0M | $353.6M |
| Cash & equivalents | $99.3M | $76.4M | $90.4M | $93.3M | $72.5M | $67.8M | $101.2M | $78.0M | $185.3M | $68.4M | $67.6M | $51.9M |
| Short-term investments | $123.7M | $178.4M | $205.3M | $233.6M | $281.5M | $314.7M | $318.8M | $371.3M | $284.5M | $259.0M | $284.4M | $301.7M |
| Receivables | $816,000 | $2.3M | $1.2M | $3.2M | $1.2M | $2.0M | $3.7M | $2.6M | $7.7M | $77.5M | $5.9M | $5.0M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$3.8M | $0 | $1 | $1 | −$5.0M |
| Other current assets | $8.9M | $9.7M | $9.4M | $8.2M | $14.0M | $18.6M | $16.4M | $17.2M | $12.1M | $9.2M | $11.9M | $29.5M |
| Total current assets | $232.7M | $266.9M | $306.3M | $338.3M | $369.1M | $403.2M | $440.0M | $465.3M | $489.5M | $414.2M | $369.8M | $383.0M |
| Property, plant & equipment (net) | $62.8M | $65.3M | $67.8M | $70.5M | $75.5M | $79.1M | $82.0M | $84.6M | $87.7M | $90.0M | $92.7M | $95.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $3.4M | $3.4M | $3.4M | $4.1M | $4.1M | $4.2M | $4.2M | $4.7M | $4.7M | $6.7M | $6.7M | $6.9M |
| Total assets | $298.9M | $335.5M | $377.4M | $412.9M | $448.8M | $486.5M | $526.3M | $554.6M | $582.0M | $510.8M | $469.2M | $485.0M |
| Liabilities | ||||||||||||
| Accounts payable | $3.7M | $2.9M | $2.3M | $3.2M | $1.9M | $2.2M | $4.3M | $1.3M | $1.6M | $2.5M | $3.3M | $752,000 |
| Short-term debt | $4.4M | $4.3M | $4.1M | $4.3M | $5.5M | $6.5M | $7.6M | $7.7M | $8.6M | $8.3M | $7.9M | $6.6M |
| Deferred revenue | $173,000 | $254,000 | $342,000 | $351,000 | $689,000 | $1.4M | $13.7M | $45.9M | $60.5M | $148.5M | $132.3M | $148.4M |
| Total current liabilities | $21.4M | $19.2M | $24.5M | $24.0M | $19.8M | $18.4M | $39.5M | $70.6M | $85.8M | $173.9M | $158.8M | $165.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $48.5M | $49.8M | $50.9M | $52.4M | $54.7M | $57.0M | $59.2M | $61.3M | $64.4M | $66.4M | $68.2M | $69.1M |
| Other long-term liabilities | $44.1M | $45.5M | $46.8M | $48.2M | $49.5M | $50.8M | $58.2M | $61.5M | $66.2M | $67.5M | $68.0M | $72.9M |
| Total liabilities | $65.5M | $64.7M | $71.2M | $72.2M | $69.3M | $69.2M | $97.6M | $132.1M | $152.0M | $241.5M | $226.8M | $238.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $3,000 | $3,000 | $3,000 |
| Retained earnings (deficit) | −$355.6M | −$312.8M | −$273.1M | −$233.9M | −$189.8M | −$146.7M | −$129.3M | −$130.5M | −$116.4M | −$171.5M | −$195.0M | −$185.4M |
| Accumulated other comprehensive income | $66,000 | $246,000 | $652,000 | $621,000 | $400,000 | $437,000 | −$43,000 | $972,000 | −$329,000 | −$246,000 | $195,000 | −$496,000 |
| Total shareholders' equity | $233.4M | $270.9M | $306.1M | $340.7M | $379.5M | $417.3M | $428.7M | $422.4M | $429.9M | $269.4M | $242.4M | $246.7M |
| Key figures | ||||||||||||
| Total debt | $48.5M | $49.8M | $50.9M | $52.4M | $54.7M | $57.0M | $59.2M | $61.3M | $64.4M | $66.4M | $68.2M | $69.1M |
| Net cash (debt) | $174.5M | $205.1M | $244.8M | $274.4M | $299.3M | $325.5M | $360.8M | $388.0M | $405.3M | $261.0M | $283.7M | $284.5M |
| Working capital | $211.3M | $247.7M | $281.8M | $314.2M | $349.3M | $384.8M | $400.6M | $394.7M | $403.7M | $240.2M | $211.0M | $217.6M |
| Tangible book value | $233.4M | $270.9M | $306.1M | $340.7M | $379.5M | $417.3M | $428.7M | $422.4M | $429.9M | $269.4M | $242.4M | $246.7M |
| Book value per share | $5.53 | $6.47 | $7.40 | $8.22 | $9.18 | $10.16 | $9.96 | $10.40 | $12.11 | $7.74 | $7.26 | $7.09 |
| Shares outstanding | 42.2M | 41.8M | 41.4M | 41.5M | 41.3M | 41.1M | 43.1M | 40.6M | 35.5M | 34.8M | 33.4M | 34.8M |
| Current ratio | 10.89 | 13.90 | 12.53 | 14.08 | 18.64 | 21.88 | 11.15 | 6.59 | 5.70 | 2.38 | 2.33 | 2.32 |
| Quick ratio | 10.47 | 13.40 | 12.14 | 13.74 | 17.94 | 20.86 | 10.73 | 6.40 | 5.56 | 2.33 | 2.25 | 2.17 |
| Debt / equity | 0.21 | 0.18 | 0.17 | 0.15 | 0.14 | 0.14 | 0.14 | 0.15 | 0.15 | 0.25 | 0.28 | 0.28 |
| Equity / assets | 78.1% | 80.7% | 81.1% | 82.5% | 84.6% | 85.8% | 81.4% | 76.2% | 73.9% | 52.7% | 51.7% | 50.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
TRDA financial position
At the end of fiscal 2025 (December 31, 2025), Entrada Therapeutics had total assets of $377.4 million (down 28.3% from a year earlier), total liabilities of $71.2 million and shareholders' equity of $306.1 million. It held $295.7 million in cash and short-term investments against $50.9 million of debt, a net cash position of $244.8 million. Its current ratio was 12.53. In the latest quarter (ended June 30, 2026) total assets were $298.9 million and equity $233.4 million.
Related: TRDA income statement, TRDA cash flow statement, TRDA key metrics. See the TRDA stock overview for the latest quote and news.
TRDA balance sheet FAQ
What are Entrada Therapeutics's total assets?
Entrada Therapeutics reported total assets of $377.4 million at the end of fiscal 2025 (December 31, 2025), compared with $526.3 million a year earlier.
How much debt does Entrada Therapeutics have?
Entrada Therapeutics had $50.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.17.
How much cash does Entrada Therapeutics have?
Entrada Therapeutics held $295.7 million in cash and short-term investments at the end of fiscal 2025; with $50.9 million of debt that is net cash of $244.8 million.
What is Entrada Therapeutics's book value?
Entrada Therapeutics's shareholders' equity (book value) was $306.1 million at the end of fiscal 2025, or $7.40 per share.
What is Entrada Therapeutics's current ratio?
Entrada Therapeutics had current assets of $306.3 million and current liabilities of $24.5 million, a current ratio of 12.53 (it can cover its short-term obligations).